Early Response to Tyrosine Kinase Inhibitors Predicts Better Outcomes in Untreated Chronic-Phase CML


Early Response to Tyrosine Kinase Inhibitors Predicts Better Outcomes in Untreated Chronic-Phase CML
Slides from a presentation at ASH 2012 and transcribed comments from a recent interview with Moshe Talpaz, MD (2/20/13)

Jain P et al. Early molecular and cytogenetic response predict for better outcomes in untreated patients with CML-CP — Comparison of 4 TKI modalities (standard- and high-dose imatinib, dasatinib and nilotinib). Proc ASH 2012;Abstract 70.

Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.